7,547.12

-173.27

-2.24%

51,652.97

-689.59

-1.32%

25,287.92

-896.81

-3.42%

2,791.26

-67.96

-2.38%

4.9210

-0.0680

-1.36%

21.94

+4.74

+27.59%

3,889.10

-142.30

-3.53%

76,292.86

-4,450.43

-5.51%

Crude Oil Dec 26

104.39

+2.39

+2.34%

US Private Equity

10,932.82

-7.68

-0.07%

NasdaqGM - Nasdaq Real Time Price USD

Zai Lab Limited (ZLAB)

22.04 -0.32 (-1.43%)

As of 3:16:12 PM EDT. Market Open.

Trade Zai Lab on Coinbase

Loading Chart for ZLAB

Chart Range Bar

Interval:

In partnership with ChartIQ

Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study

Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial

Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial

Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces $250 Million Private Placement

Zai Lab Announces $250 Million Private Placement

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?

Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks

Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks

Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics

Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics

Mobilize your Website

View Site in Mobile | Classic

Share by: